|Bid||1.91 x 900|
|Ask||2.30 x 1800|
|Day's Range||1.8900 - 2.2300|
|52 Week Range||0.7250 - 3.0000|
|Beta (3Y Monthly)||-1.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 27, 2019 - Apr 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
Sigma Labs, Inc. (SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, has been awarded a Test and Evaluation Program contract with a leading global materials and service provider in additive manufacturing (AM). Sigma Labs is installing multiple PrintRite3D INSPECT 4.0 in-process quality assurance systems located in the customer’s German and United States facilities under the Sigma Rapid Test and Evaluation Program.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
3D printing, or additive manufacturing, is an exciting and dynamic sector. 3D printing has the ability to change the way products are developed, manufactured, purchased and acquired. Currently there are a variety of stocks that focus on 3D printing.
SANTA FE, N.M., Dec. 04, 2018 -- Sigma Labs, Inc. (NASDAQ: SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, has.
Sigma Labs, Inc. (SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, announced that John Rice, Chief Executive Officer of Sigma Labs, will be a featured presenter at the LD Micro Main Event on Tuesday, December 4, 2018 at 4:30 PM Pacific Time.
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Conference Call to Be Held Friday, November 16, 2018 at 8:30am Eastern Time SANTA FE, N.M., Nov. 14, 2018 -- Sigma Labs, Inc. (NASDAQ: SGLB) (“Sigma Labs,” “we," "our" or the.
Sigma Labs, Inc. (SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, will issue financial results for the third quarter ended September 30, 2018 on Monday, November 12, 2018 after market trading hours. A conference will be held that day at 4:30 pm ET to review financial results and corporate highlights. Participating in the call will be John Rice, Chairman and CEO, and Nannette Toups, CFO.
Sigma Labs, Inc. (SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, will launch the newest configuration of its PrintRite3D® quality control solution—incorporating PrintRite3D® SENSORPAK® 4.0 hardware and PrintRite3D® INSPECT® 4.0 software—at Formnext 2018, the leading trade fair for Additive Manufacturing, in Frankfurt, Germany on November 13-16. The Company will be exhibiting its technology and meeting with potential customers at Booth 3.0-H77. “Our latest PrintRite3D® suite of products presents a significant value proposition to OEMs and manufacturers, as it is designed to increase production yield of 3D metal manufactured parts and to shorten time to market, removing a major hurdle that has been affecting manufacturers,” said John Rice, CEO of Sigma Labs.
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Sigma Labs, Inc. (NASDAQ: SGLB ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern Time. ...
LONDON, UK / ACCESSWIRE / June 27, 2018 / If you want a free Stock Review on SABR sign up now at www.wallstequities.com/registration. This Wednesday, WallStEquities.com has initiated reports coverage on the following Information Technology Services equities: NCR Corp. (NYSE: NCR), Qudian Inc. (NYSE: QD), Sabre Corp. (NASDAQ: SABR), and Sigma Labs Inc. (NASDAQ: SGLB).
NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Oragenics and Sigma Labs were both big winners in the biotech arena on Wednesday. Shares of Oragenics climbed higher after announcing positive results from its interim safety analysis on patients from its Phase 2 clinical trial of AG013. AG013 is a promising product for the prevention of oral mucositis in cancer patients.